Impact of leukapheresis on early death rate in adult acute myeloid leukemia presenting with hyperleukocytosis
- 18 September 2007
- journal article
- Published by Wiley in Transfusion
- Vol. 47 (10), 1843-1850
- https://doi.org/10.1111/j.1537-2995.2007.01406.x
Abstract
BACKGROUND: Patients with acute myeloid leukemia (AML) with hyperleukocytosis of at least 100 × 109 per L are at high risk of early death due to pulmonary or cerebral leukostasis. Although the efficacy of leukapheresis in terms of prompt cytoreduction is generally accepted, published data regarding the clinical value of immediate therapeutic leukapheresis are limited and conflicting. STUDY DESIGN AND METHODS: To determine whether leukapheresis has a favorable impact on early mortality, the clinical course of 53 newly diagnosed patients with AML and hyperleukocytosis admitted between 1995 and 2005 was analyzed retrospectively. Before August 2001, 28 patients received chemotherapy without leukoreduction (Cohort A). Thereafter, all AML patients with hyperleukocytosis were scheduled to receive leukapheresis, which was performed in 25 patients (Cohort B). RESULTS: There were no procedure-related adverse events. By Day 21 of therapy, 13 of 53 patients had died, resulting in an overall early death rate of 25 percent. In a multivariate logistic regression model, patients in Cohort B had a significantly lower risk of early death than patients in Cohort A (16% vs. 32%, respectively; p = 0.015). Dyspnea (p = 0.005), elevated creatinine (p = 0.028), and higher lactate dehydrogenase serum levels (p = 0.021) were independent risk factors for early death. With a median follow-up of 24.2 months, the overall survival was similar in both cohorts (Cohort A, 7.5; Cohort B, 6.5 months). Thus, leukapheresis had no impact on patients' long-term survivals. CONCLUSIONS: Our experience suggests that AML patients with hyperleukocytosis receiving leukapheresis had a significantly lower risk for early death by Day 21 than patients treated without leukapheresis. We therefore have adopted leukapheresis as a standard procedure in our department.Keywords
This publication has 20 references indexed in Scilit:
- Interaction of ICAM‐1 with β2‐integrin CD11c/CD18: Characterization of a peptide ligand that mimics a putative binding site on domain D4 of ICAM‐1European Journal of Immunology, 2005
- Early Deaths and Treatment-Related Mortality in Children Undergoing Therapy for Acute Myeloid Leukemia: Analysis of the Multicenter Clinical Trials AML-BFM 93 and AML-BFM 98Journal of Clinical Oncology, 2004
- Risk-adapted induction and consolidation therapy in adults with de novo AML aged ≤ 60 years: results of a prospective multicenter trialAnnals of Hematology, 2004
- Leukapheresis Reduces Early Mortality in Patients with Acute Myeloid Leukemia with High White Cell Counts But Does Not Improve Long Term SurvivalLeukemia & Lymphoma, 2001
- Hyperleukocytic Leukemias and Leukostasis: A Review of Pathophysiology, Clinical Presentation and ManagementLeukemia & Lymphoma, 2000
- The I domain is a major recognition site on the leukocyte integrin Mac-1 (CD11b/CD18) for four distinct adhesion ligands.The Journal of cell biology, 1993
- Pulmonary leukostasis without hyperleukocytosis: A clinicopathologic study of 16 casesAmerican Journal of Hematology, 1992
- Acute myeloblastic leukemia with hyperleukocytosis: Risk factors for early mortality in inductionAmerican Journal of Hematology, 1988
- Pulmonary leukostasis as the single worst prognostic factor in patients with acute myelocytic leukemia and hyperleukocytosisAmerican Journal Of Medicine, 1985
- INTRAVASCULAR LEUKOCYTE THROMBI AND AGGREGATES AS A CAUSE OF MORBIDITY AND MORTALITY IN LEUKEMIAMedicine, 1974